These findings further support that the antirheumatoid activity of TMZ could be attributed to its potential to target the inflammatory TRAF6/IRAK pathway in the paw tissues of the RA model, with a preference effect for combination treatment with MTX. The gene discussed is TRAF6; the disease is rheumatoid arthritis.